ALX reports $48.3M cash; CD47 predictive of evorpacept response in HER2+ breast cancer Phase 1b/2

ALX ONCOLOGY HOLDINGS INC

Preliminary cash, cash equivalents, and investments total $48.3M as of Dec 31, 2025.
Phase 1b/2 trial data show CD47 expression is predictive of evorpacept response in HER2+ metastatic breast cancer.
In 9 confirmed HER2+ patients, cORR was 56% (5/9) with median PFS of 7.4 months (prior SABCS2024 data).
Full biomarker analysis submitted for presentation at an upcoming scientific conference.
Results align with ASPEN-06 gastric cancer trial, strengthening confidence in ongoing ASPEN-09-Breast Phase 2 trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.